Abstract
Comprehensive evidence supports that oligomerization and accumulation of amyloidogenic Aβ42 peptides in brain is crucial in the pathogenesis of both familial and sporadic forms of Alzheimers disease. Imaging studies indicate that the buildup of Aβ begins many years before the onset of clinical symptoms, and that subsequent neurodegeneration and cognitive decline may proceed independently of Aβ. This implies the necessity for early intervention in cognitively normal individuals with therapeutic strategies that prioritize safety. The aspartyl protease γ-secretase catalyses the last step in the cellular generation of Aβ42 peptides, and is a principal target for anti-amyloidogenic intervention strategies. Due to the essential role of γ-secretase in the NOTCH signaling pathway, overt mechanism-based toxicity has been observed with the first generation of γ-secretase inhibitors, and safety of this approach has been questioned. However, two new classes of small molecules, γ-secretase modulators (GSMs) and NOTCH-sparing γ-secretase inhibitors, have revitalized γ-secretase as a drug target in AD. GSMs are small molecules that cause a product shift from Aβ42 towards shorter and less toxic Aβ peptides. Importantly, GSMs spare other physiologically important substrates of the γ-secretase complex like NOTCH. Recently, GSMs with nanomolar potency and favorable in vivo properties have been described. In this review, we summarize the knowledge about the unusual proteolytic activity of γ-secretase, and the chemical biology, molecular mechanisms and clinical perspective of compounds that target the γ-secretase complex, with a particular focus on GSMs.
Keywords: Alzheimer's disease, neurodegeneration, amyloid-β peptide, gamma-secretase, gamma-secretase modulators, A 42 peptides, Secretase Complex, N peptides, NOTCH intracellular domain (NICD)
Current Neuropharmacology
Title: Chemical Biology, Molecular Mechanism and Clinical Perspective of γ - Secretase Modulators in Alzheimers Disease
Volume: 9 Issue: 4
Author(s): Bruno Bulic, Julia Ness, Stefanie Hahn, Andreas Rennhack, Thorsten Jumpertz and Sascha Weggend
Affiliation:
Keywords: Alzheimer's disease, neurodegeneration, amyloid-β peptide, gamma-secretase, gamma-secretase modulators, A 42 peptides, Secretase Complex, N peptides, NOTCH intracellular domain (NICD)
Abstract: Comprehensive evidence supports that oligomerization and accumulation of amyloidogenic Aβ42 peptides in brain is crucial in the pathogenesis of both familial and sporadic forms of Alzheimers disease. Imaging studies indicate that the buildup of Aβ begins many years before the onset of clinical symptoms, and that subsequent neurodegeneration and cognitive decline may proceed independently of Aβ. This implies the necessity for early intervention in cognitively normal individuals with therapeutic strategies that prioritize safety. The aspartyl protease γ-secretase catalyses the last step in the cellular generation of Aβ42 peptides, and is a principal target for anti-amyloidogenic intervention strategies. Due to the essential role of γ-secretase in the NOTCH signaling pathway, overt mechanism-based toxicity has been observed with the first generation of γ-secretase inhibitors, and safety of this approach has been questioned. However, two new classes of small molecules, γ-secretase modulators (GSMs) and NOTCH-sparing γ-secretase inhibitors, have revitalized γ-secretase as a drug target in AD. GSMs are small molecules that cause a product shift from Aβ42 towards shorter and less toxic Aβ peptides. Importantly, GSMs spare other physiologically important substrates of the γ-secretase complex like NOTCH. Recently, GSMs with nanomolar potency and favorable in vivo properties have been described. In this review, we summarize the knowledge about the unusual proteolytic activity of γ-secretase, and the chemical biology, molecular mechanisms and clinical perspective of compounds that target the γ-secretase complex, with a particular focus on GSMs.
Export Options
About this article
Cite this article as:
Bulic Bruno, Ness Julia, Hahn Stefanie, Rennhack Andreas, Jumpertz Thorsten and Weggend Sascha, Chemical Biology, Molecular Mechanism and Clinical Perspective of γ - Secretase Modulators in Alzheimers Disease, Current Neuropharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157015911798376352
DOI https://dx.doi.org/10.2174/157015911798376352 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Emotion (Dys)regulation: An integration of Pharmacological, Neurobiological, and Psychological Frameworks
Emotion regulation is a critical aspect of mental well-being and interpersonal relationships. To fully understand and effectively address emotion regulation, an integrative approach that considers pharmacological, neurobiological, and psychological frameworks is essential. Pharmacological interventions, such as medications targeting neurotransmitter imbalances, can play a significant role in managing emotional dysregulation. Understanding ...read more
Intercellular Communications in Cerebral Ischemia
Cerebral ischemia, a condition in which there is inadequate blood supply to the brain, ranks as one of the leading causes of disability and mortality globally. Despite its prevalence and severity, efficacious treatment options for this debilitating disorder remain limited. Recent scientific explorations have delved deeply into the pathological mechanisms ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Diosgenin <i>via</i> NMDA Receptor Exerted Anxiolytic-like Effect on Maternally Separated Mice
Current Pharmaceutical Design Frequency of Depression and its Correlation with Serum Carnitine Level in HIV/AIDS Patients
Current HIV Research Ubiquitin Ligases as Key Elements for the Modulation of the Immune Response: An Insight in the Pathogenesis of Autoimmunity
Current Rheumatology Reviews β-Hydroxy-β-Methylbutyrate as a Countermeasure for Cancer Cachexia: A Cellular and Molecular Rationale
Anti-Cancer Agents in Medicinal Chemistry The Role of Mesenchymal Stem Cells in Immune Response
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Management of Adverse Effects from Medications Used to Treat Substance Use Disorders
Current Psychopharmacology Meet Our Editorial Board Member
Current Neuropharmacology Cholinergic Drugs as Therapeutic Tools in Inflammatory Diseases: Participation of Neuronal and Non-Neuronal Cholinergic Systems.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Molecular Imaging of Diabetic Pancreas
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The AICD Interacting Protein DAB1 is Up-Regulated in Alzheimer Frontal Cortex Brain Samples and Causes Deregulation of Proteins Involved in Gene Expression Changes
Current Alzheimer Research Apolipoprotein E Gene Revisited: Contribution of Rare Variants to Alzheimer’s Disease Susceptibility in Southern Chinese
Current Alzheimer Research Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis The Cognitive Effects of Wearable Cameras in Mild Alzheimer Disease – An Experimental Study
Current Alzheimer Research Diagnosis and Treatment of Common Sleep Disorders in Adolescence
Adolescent Psychiatry Vascular Inflammation During Human Rickettsioses: An Essential Host Response and a Potential Target for Supplemental Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications
Current Medicinal Chemistry Natural and Synthetic Inhibitors of Caspases: Targets for Novel Drugs
Current Drug Targets - CNS & Neurological Disorders Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose
Current Drug Safety Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF) and its Possible Role in Tumour Progression During Malignant Transformation of Atrophic Epithelium in Oral Submucous Fibrosis
Current Angiogenesis (Discontinued)